Blog
RSS FeedPosted by Michael Wonder on 20 Feb 2018
Beyond QALYs: multi-criteria based estimation of maximum willingness to pay for health technologies
20 February 2018 - The QALY is a useful outcome measure in cost-effectiveness analysis. But in determining the overall value of ...
Posted by Michael Wonder on 20 Feb 2018
The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges
20 February 2018 - Good practices for budget impact analysis have been increasingly developed since the year 2000. ...
Posted by Michael Wonder on 23 Jan 2018
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
23 January 2018 - Although health technology assessment systems base their decision making process either on economic evaluations or comparative clinical ...
Posted by Michael Wonder on 30 Oct 2017
Predictive validation and the re-analysis of cost-effectiveness: do we dare to tread?
30 October 2017 - Predictive validation (also known as fourth-order validation) involves the comparison between model outputs and observed data ...
Posted by Michael Wonder on 16 Oct 2017
Social value and individual choice: the value of a choice-based decision-making process in a collectively funded health system
4 October 2017 - Evidence about cost-effectiveness is increasingly being used to inform decisions about the funding of new technologies that ...
Posted by Michael Wonder on 09 Oct 2017
Time for a change in how new antibiotics are reimbursed: development of an insurance framework for funding new antibiotics based on a policy of risk mitigation
9 October 2017 - Healthcare systems depend on the availability of new antibiotics. ...
Posted by Michael Wonder on 27 Sep 2017
New advance value framework offered as a decision-support tool for reimbursement
25 September 2017 - Researchers at the London School of Economics and Political Science have developed a multiple criteria decision ...
Posted by Michael Wonder on 11 Sep 2017
NICE: We're the institute of 'yes'
11 September 2017 - But Meindert Boysen says affordability conversations with pharma need to happen earlier. ...
Posted by Michael Wonder on 24 Jul 2017
Managing conflicts of interest – making good decisions
24 July 2017 - NICE is seeking views on a new conflicts of interest policy to ensure its committees’ decisions ...
Posted by Michael Wonder on 07 May 2017
New NICE criteria for drug access
1 May 2017 - An overhaul of NHS drug access in England by NICE and NHS England, which for the first ...
Posted by Michael Wonder on 11 Apr 2017
Policies for use of real-world data in health technology assessment: a comparative study of six HTA agencies
11 April 2017 - Health technology assessment agencies worldwide are thus exploring whether real-world data may provide alternative sources of ...
Posted by Michael Wonder on 29 Mar 2017
Charities unite to oppose NICE rare disease rules
28 March 2017 - Nearly 200 rare disease patient groups have come together to call on NICE and NHS England ...
Posted by Michael Wonder on 24 Mar 2017
Cost effective but unaffordable: an emerging challenge for health systems
23 March 2017 - New “budget impact test” is an unpopular and flawed attempt to solve a fundamentally political problem ...
Posted by Michael Wonder on 22 Mar 2017
The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions
22 March 2017 - Weakly correlated surrogates encourage payers and regulators to impose more stringent evidence thresholds. ...
Posted by Michael Wonder on 19 Jan 2017
Drug cost-saving plans may hit patients
19 January 2017 - Patients in England may face delays getting new drugs or go without them if NHS bosses ...